Reimbursement of medicines under Art. 71a–d KVV/HIO

Sanitas rejects the media portrayal: We currently facilitate therapy or a treatment trial for around 80 percent of off-label requests.

In recent days, the RTS programme “Mise au point” and several German and French-language Swiss media outlets have reported significant differences in approval rates for the off-label use of medicines under Article 71a–d KVV/HIO. 

We understand that these reports may cause uncertainty. When it comes to serious illnesses, no decision should be taken lightly. However, the figures cited by RTS are outdated (2017–2019) and do not match our data: Sanitas approves treatment or a therapeutic trial in around 80% of applications. We therefore dispute the version presented by RTS. 

Sanitas is firmly committed to ensuring that seriously ill patients have access to innovative therapies when these are covered by compulsory health insurance. At the same time, we are legally required to review requests to cover costs carefully on a case-by-case basis. In doing so, Sanitas contributes to a patient-centred, solidarity-based and sustainable healthcare system in Switzerland. Requests for cost coverage are also assessed by independent, officially appointed medical officers who work with various health insurers.

Approval rate for applications for essential medicines 


The figures cited in the media are taken from an evaluation commissioned by the Federal Office of Public Health (FOPH) in 2020. The data covers the years 2017 to 2019. The study’s authors note that insurers recorded their applications in different ways, meaning that their approval rates are therefore “not directly comparable”. They describe a comparison across all insurers as “problematic”. 

According to our own data, we approve treatment or a therapeutic trial in around 80% of applications under Art. 71a–d KVV/HIO. 

However, it is important for us to emphasise that even current figures are only comparable to a limited extent. This is because, despite data collection now being more standardised, there are still significant differences – for example, in the allocation of applications or the composition of the pools of policyholders. Reimbursement of medicines on a case-by-case basis is a complex issue. A simple ranking of insurers does not do justice to this complexity.

What is Article 71 a-d KVV/HIO, and what is its significance?


Article 71 a–d of the Health Insurance Ordinance (KVV/HIO) sets out the conditions under which basic insurance must cover the costs of medicines that are not routinely reimbursed for the treatment in question – for example, when used outside their approved indication (off-label use). The prerequisites include a serious or life-threatening condition, the absence of an established effective alternative, and the expectation of a significant therapeutic benefit.  

Health insurers are legally required to assess each application individually, based on the requirements of mandatory health insurance and the medical evaluation. The independent medical officers appointed for this purpose play a key role in this process. In particular, they assess the treatment’s expected effectiveness, appropriateness and cost-effectiveness. The aim is to provide access to effective treatments while ensuring that reimbursement is consistent, fair and legally compliant.

With medical advances bringing new medicines and new combinations of therapies, the option of reimbursement on a case-by-case basis under Art. 71 a–d KVV/HIO is likely to become increasingly important in the future. A case-by-case assessment under Article 71a–d KVV/HIO gives people with serious or life-threatening illnesses access to these innovations.